SlideShare a Scribd company logo
1 of 43
Dr. Ayush Garg
1
CANCER VACCINES
Historical Perspective
• Oldest description of cancer was discovered in Egypt and dates back
to about 3000 BC.
• 1777 Nooth, surgeon to Duke of Kent, inoculated himself with cancer
tissue from patient.
• 1808 Alibert, physician to Louis XVIII, received an injection of breast
cancer material.
• In 1970s, scientists mass produced monoclonal antibodies that are
specifically targeted against cancer cells.
2
3
INTRODUCTION
• The aim of cancer vaccines is to stimulate the immune system to be
able to recognise cancer cells as abnormal and destroy them.
• There are two major categories that cancer vaccines fit into:
1.Specific cancer vaccine
2.Universal cancer vaccine
• Each type of cancer vaccine works on the same basic idea that the
vaccine, which contains tumor cells or antigens, stimulates the
patient's immune system, which produces special cells that kill
cancer cells and prevent relapses of the cancer. (In Animation)
4
Cancer vaccines are medicines that belong to a class of substances known as
biological response modifiers. Biological response modifiers work by
stimulating or restoring the immune system’s ability to fight infections and
disease.
Two broad types of cancer vaccines:
•Preventive (or prophylactic) vaccines
prevent cancer from developing in healthy people.
•Treatment (or therapeutic) vaccines
treat an existing cancer by strengthening the
body’s natural defenses against the cancer.
Cancer vaccines
Antitumor response of prophylactic vaccine
• Given to people who have very high risk of developing cancers that have
been diagnosed with premalignant changes in tissues
• Vaccine based antigen along with immunomodulatory is introduced that
activate the Langerhan's cells.
• T cells are activated when the tumor antigen is presented to them along
with B cells that produce tumor specific antibodies
• Clonal expansion is the next process that occurs along with the memory cell
formation.
• In future if tumor start its growth tumor specific memory cells will be
reactivated by the tumor antigen reaching lymph nodes
• Secondary immune response
1.Large number of effector T cells
2.High titer of antibodies
3.Continues activation of DC at the site
• Tumor will not be allowed to grow large and is easily eliminated as a result
of secondary immune response.
Anti tumor response of therapeutic
vaccine
• Administered after tumor diagnosis when tumor is interacting with
immune system.
• Vaccine (autologous/defined tumor antigen + immunomodulators) to
activate Langerhan’s cells.
• Taken up by activated Langerhan's cells and presented to T cells
• B-cell activated, clonal expansion, production of tumor specific
antibodies.
• Migration of tumor sensitive T cells at site of tumor metastasis.(attempt
to kill tumor cells expressing vaccine Ag.)
• Immunosuppressive tumor microenvironment suppresses their function.
• Establishment of tumor heterogeneity. Leading to lost of tumor antigen
expression or resistance immune effectors mechanism evading immune
evasion.
• Tumor cells with antigen not recognized by T-cells and Ab. They are
resistant to immune destruction.
TYPES OF CANCER VACCINES:
10
Types of
Cancer
Vaccines
Types of
Cancer
Vaccines
Dendritic
cell
vaccines
Antigen
vaccines
Tumour
cell
vaccine
DNA
vaccine
Anti
idiotype
vaccine
Antigen vaccine
11
• These use tumor-specific antigens - proteins displayed on a tumor
cell - to stimulate the immune system.
• By injecting these antigens into the cancerous area of the patient,
the immune system will produce an increased amount of antibodies
or cytotoxic T lymphocytes, also known as killer T cells, to attack
cancer cells that carry that specific antigen.
• Multiple antigens can be used in this type of vaccine to vary the
immune system response.
Anti-idiotype Vaccines:
• Some antibodies, called idiotype antibodies, act as antigens,
triggering an immune response.
• Primary target is LYMPHOMA.
12
Dendritic Cell Vaccines:
• Dendritic cells break the antigens on the cancer
cell surfaces into smaller pieces.
• The dendritic cells then act as most-wanted posters for the immune
system, displaying those antigen pieces to the killer T cells.
• In order to make dendritic cell vaccines some of the patient's
dendritic cells are extracted and immune cell stimulants are used to
reproduce large amounts of dendritic cells in the lab.
• These dendritic cells are then exposed to antigens from the patient's
cancer cells.
• This combination of dendritic cells and antigens is then injected into
the patient and the dendritic cells work to program the T cells.
13
Tumor Cell Vaccines (Autologous
/Allogeneic
Tumor Cells):
• Autologous and allogeneic tumor cells were one of the first types of
tumor vaccines to be used.
• The main advantage of tumor cell vaccines is that they have all the
relevant tumor antigens needed by the immune system to mount an
effective antitumor response.
• A second advantage is that tumor cell-based immunization allows the
development of cancer vaccines without knowing the specific
antigens.
14
DNA Vaccines
• Bits of DNA from the patient's cells are injected into the patient,
which instructs the other cells to continuously produce certain
antigens.
• This DNA vaccine increases production of antigens, which forces the
immune system to respond by producing more T cells.
• The idea of these vaccines is that the body would be provided with a
constant supply of antigens to allow the immune response to continue
against the cancer.
15
Cancer Vaccine Preparation:
• Cancer vaccines are made from the person’s own cancer cells or from
cells that are grown in a laboratory.
• The cancer cells are treated with heat or radiation, then they
become inactive and can be used for vaccine preparation.
• Certain proteins may then be taken from the cancer cells and used to
make a cancer vaccine.
• Often a cancer vaccine will also contain substances that are already
known to boost the immune system, such as BCG.
16
TUMOR CELL VACCINES:
17
• Mode of Delivery: Cancer vaccines are usually a liquid which is given
by an intradermal injection.
• The Possible Side Effects: The possible side effects of cancer vaccines
include a skin reaction at the injection site, a skin rash or mild flu-like
symptoms.
18
Cancer Vaccines Which Are Currently
under Clinical Trials:
• Onyvax: (a monoclonal antibody 105AD7 anti-idiotype vaccine)
• It is used for the treatment of advanced colorectal adenocarcinoma.
• The vaccine is administered endemic together with the BCG vaccine
or intramuscularly together with the alum adjuvant.
19
• OncoVAX
• Autologous vaccine for Stage II colon
cancer.
• Received fast-track status from FDA
in 2006.
• STUDY: 254 patients received either
OncoVAX or placebo.
• Improves 5-year survival and
recurrence-free interval.
• 57.1% relative risk reduction.
Cancer VAX
• It is being used together with the surgical treatment in the treatment
of melanoma III stage.
• In order to increase the cellular immune response, this vaccine is
given together with the BCG Vaccine.
20
NY-ESO-1 Peptide Vaccine
• It is used endermic in the treatment of Soft tissue Sarcoma Stage II-
IV expressing NY-ESO-1,LAGE antigen NY-ESO-1 or LAGE antigen .
• Granulocyte-macrophage colony stimulating factor (GM- CSF) is to be
injected, subcutaneous, in additional to this vaccine.
A Monoclonal Antibody 11D10Anti-
idiotype Vaccine and Monoclonal
Antibody 3h1 Anti-idiotype Vaccine
• They are being used in the treatment of the patients with stage II or
IIIA non-small cell lung cancer (T1-3, N1-2, M0)
• It is administered starting from the 14-45 days after operation.
21
GP100 AND MART-1
• A vaccine therapy using Tyrosinase, GP100 and MART-1
peptides together with the alum adjuvant is being used for the
treatment of the patients with IIB IIC, III, or IV cutaneous
melanoma OR stage III or IV ocular or mucosal melanoma.
• Interleukin-12 and the granulocyte-macrophage colony-
stimulating factor (GM-CSF) are also used beside the vaccine.
22
ALVAC-CEA/B7.1
• A deactivated strain of a virus, is being tested for the treatment
of metastatic colorectal cancer.
• Virus antigens are identical to the antigens exhibited by
colorectal tumors.
• The vaccine is administered immediately upon diagnosis along
with chemotherapy.
23
VG-1000 Vaccine
• This vaccine is most beneficial in treating carcinomas and
melanomas.
• Patients subjected to chemotherapy or radiation respond more
slowly to VG-1000 as they have a depressed immune system,
however, patients who have had neither radiation nor
chemotherapy respond favourably indicating it as first-line
treatment for persons with recently diagnosed cancers, as well
as to help prevent recurrence.
24
HSPPC-96, or Oncophage®
• The vaccine is a heat-shock protein, a class of compounds that has
shown activity as autologous therapy
• The therapeutic agent is derived from and tailored to the tumors of
individual patients.
• The HSPPC-96 vaccine contains antigens extracted from melanoma.
• Some of these antigens, like MART-1 and GP100, are unique to
melanoma; others are found in many types of cancer.
25
Sipuleucel-T
• Dendritic cell vaccine approved for treatment of
asymptomatic or minimally symptomatic metastatic
castrate-resistant (hormone refractory) prostate cancer.
• Target-prostatic acid phosphatase (PAP), which is found in
95% of prostate cancers.
• RESULTS
• In the sipuleucel-T group, there was a relative reduction of 22% in the risk
of death as compared with the placebo group.
• This reduction represented a 4.1-month improvement in median survival.
• The 36-month survival probability was 31.7% in the sipuleucel-T group
versus 23.0% in the placebo group.
• CONCLUSIONS
• The use of sipuleucel-T prolonged overall survival among men with
metastatic castration-resistant prostate cancer.
• No effect on the time to disease progression was observed.
27
Indications (NCCN Version 1.2017)
28
DOSAGE AND ADMINISTRATION
• For intravenous use only.
• Administer 3 doses at approximately 2-week intervals.
• Premedicate patients with oral acetaminophen and an antihistamine.
• Infuse Sipuleucel-T intravenously over 60 minutes.
• The most common adverse reactions (incidence ≥ 15%) are chills,
fatigue, fever, back pain, nausea, joint ache, and headache.
29
 Note: The three-course treatment will cost $93,000.
 Mechanism of action of Sipuleucel T ‑
31
HPV Vaccine
• Gardasil: The FDA approved Gardasil for people ages 9 to 26 years to
prevent:
• Cervical, vaginal, and vulvar cancers in girls and women
• Anal cancer in women and men
• Genital warts in men and boys
• The vaccine protects against the human papillomavirus (HPV).
• Cervarix: This vaccine also protects against HPV infection. The FDA
approved it for the prevention of cervical cancer in girls and women
ages 9 to 25 years.
• The first HPV vaccine became available in 2006.
32
• According to Centers for Disease Control and Prevention (CDC)
Guidelines and Advisory Committee on Immunization Practices
(ACIP) November 4,2016.
• HPV vaccination is not currently recommended for women over age
26 years.
• Clinical trials showed that, overall, HPV vaccination offered women
limited or no protection against HPV-related diseases.
• For women over age 26 years, the best way to prevent cervical
cancer is to get routine cervical cancer screening, as recommended.
• Available vaccines protect against either two, four, or nine types of
HPV so they are either Bivalent, Quadrivalent or Ninevalent
respectively.
33
Gardasil 9
• Gardasil 4 got approval by FDA in 2006
Gardasil 9 in Dec,2014.
• GARDASIL 9 is a vaccine indicated in girls and women 9 through 26
years of age for the prevention of the following diseases:
• Cervical, vulvar, vaginal, and anal cancer caused by Human
Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58
• Genital warts (condyloma acuminata) caused by HPV types 6 and 11
• GARDASIL 9 is indicated in boys and men 9 through 26 years of age
for the prevention of the following diseases:
• Anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58
• Genital warts (condyloma acuminata) caused by HPV types 6 and 11
34
35
Age Regimen Schedule
9 through 14 years 2 dose 0,6 to 12 months
3 dose 0,2,6 months
15 through 26 years 3 dose 0,2,6 months
• Each dose of GARDASIL 9 is 0.5-mL.
• GARDASIL 9 should be administered intramuscularly in the deltoid
region of the upper arm or in the higher anterolateral area of the thigh.
• All three vaccines are given through a series of three injections into
muscle tissue over a 6-month period.
• In October 2016, the FDA approved a 2-dose schedule for boys and
girls initiating vaccination with Gardasil 9 at ages 9 to 14 years (the
second dose is to be administered 6–12 months after the first)
Cervarix
• CERVARIX is a vaccine indicated for the prevention of the following
diseases caused by oncogenic human papillomavirus (HPV) types 16 and
18:
• Cervical cancer,
• Cervical intraepithelial neoplasia (CIN) Grade 2 or worse and
adenocarcinoma in situ, and
• Cervical intraepithelial neoplasia (CIN) Grade 1.
• CERVARIX is approved for use in females 9 through 25 years of age.
• Three doses (0.5-mL each) by intramuscular injection according to the
following schedule: 0, 1, and 6 months.
• The preferred site of administration is the deltoid region of the upper
arm.
36
Role of Adjuvants in cancer vaccines?
• Substances known as adjuvants are often added to vaccines to boost
their ability to induce potent anticancer immune responses.
• Some microbes, such as the bacterium Bacillus Calmette-
Guérin (BCG).
• BCG is used to treat early stage bladder cancer. It is a liquid put into
the bladder through a catheter.
• BCG attracts the body’s immune system cells to the bladder, where
they can attack the bladder cancer cells.
• Treatment with BCG can cause symptoms that are like:
• Flu like symptoms such as fever, chills, and fatigue.
• It can also cause a burning feeling in the bladder.
37
Side Effects of Cancer Vaccine
• The most commonly reported side effect of cancer vaccines is
• Inflammation at the site of injection, including redness, pain,
swelling, warming of the skin, itchiness, and occasionally a rash.
• People sometimes experience flu-like symptoms after receiving a
cancer vaccine, including fever, chills, weakness, dizziness, nausea or
vomiting, muscle ache, fatigue, headache, and occasional breathing
difficulties.
• These side effects, which usually last for only a short time, indicate
that the body is responding to the vaccine and making an immune
response, as it does when exposed to a virus.
38
• Thalidomide:
• treatment for multiple myeloma
• Lenalidomide:
• Newer drug , treatment for multiple myeloma
• Bacille Calmette-Guérin:
• treatment of superficial forms of bladder cancer
• Colorectal cancer
• Lung cancer
• Melanoma
• Medicinal mushrooms:
• Agaricus subrufescens -anticancer properties
Other drugs that boost the immune system
40
41
CONCLUSION:
May be more effective in cancers that are not advanced.
More research still needs to be done including larger
studies.
Researchers are actively trying to overcome hurdles in the
making of these vaccines.
Could make a big impact on our approach to cancer.
Most importantly these vaccines could mean better
quality of life and longer survival for patients!!
42
THANK
YOU
43

More Related Content

What's hot

Trastuzumab
TrastuzumabTrastuzumab
Trastuzumab
madurai
 
Oncotype Dx Mammaprint
Oncotype Dx MammaprintOncotype Dx Mammaprint
Oncotype Dx Mammaprint
fondas vakalis
 

What's hot (20)

Targeted cancer therapies
Targeted cancer therapiesTargeted cancer therapies
Targeted cancer therapies
 
Tumor microenvironment in the body
Tumor microenvironment in the bodyTumor microenvironment in the body
Tumor microenvironment in the body
 
Cancer Immunotherapy
Cancer ImmunotherapyCancer Immunotherapy
Cancer Immunotherapy
 
Cancer vaccines Presentation
Cancer vaccines PresentationCancer vaccines Presentation
Cancer vaccines Presentation
 
Cancer vaccine
Cancer vaccineCancer vaccine
Cancer vaccine
 
TUMOR microenvironment
TUMOR microenvironment TUMOR microenvironment
TUMOR microenvironment
 
Trastuzumab
TrastuzumabTrastuzumab
Trastuzumab
 
Oncogene and tumor suppressor gene
Oncogene and tumor suppressor geneOncogene and tumor suppressor gene
Oncogene and tumor suppressor gene
 
Hallmarks of cancer
Hallmarks of cancerHallmarks of cancer
Hallmarks of cancer
 
Tumor And Microenvironment
Tumor And MicroenvironmentTumor And Microenvironment
Tumor And Microenvironment
 
Cancer vaccines
Cancer vaccinesCancer vaccines
Cancer vaccines
 
Cancer immunotherapy
Cancer immunotherapy Cancer immunotherapy
Cancer immunotherapy
 
Immunotherapy for cancer
Immunotherapy for cancer Immunotherapy for cancer
Immunotherapy for cancer
 
Molecular methods in oncology
Molecular methods in oncology Molecular methods in oncology
Molecular methods in oncology
 
Breast Cancer: A focus on BRCA Mutations.
Breast Cancer: A focus on BRCA Mutations.Breast Cancer: A focus on BRCA Mutations.
Breast Cancer: A focus on BRCA Mutations.
 
Oncotype Dx Mammaprint
Oncotype Dx MammaprintOncotype Dx Mammaprint
Oncotype Dx Mammaprint
 
the role of miRNA in cancer
the role of miRNA in cancerthe role of miRNA in cancer
the role of miRNA in cancer
 
Cancer Pathways
Cancer PathwaysCancer Pathways
Cancer Pathways
 
tumor suppressor gene, prb, p53 gene
tumor suppressor gene, prb, p53 genetumor suppressor gene, prb, p53 gene
tumor suppressor gene, prb, p53 gene
 
Hallmarks in cancer
Hallmarks in cancerHallmarks in cancer
Hallmarks in cancer
 

Similar to Cancer vaccines final

Similar to Cancer vaccines final (20)

Cancer vaccines
Cancer vaccinesCancer vaccines
Cancer vaccines
 
Cancer Immunotherapy and Gene Therapy
Cancer Immunotherapy and Gene TherapyCancer Immunotherapy and Gene Therapy
Cancer Immunotherapy and Gene Therapy
 
IMMUNOTHERAPEUTICS.
IMMUNOTHERAPEUTICS.IMMUNOTHERAPEUTICS.
IMMUNOTHERAPEUTICS.
 
Cancer therapy via vaccine
Cancer therapy via vaccineCancer therapy via vaccine
Cancer therapy via vaccine
 
Vaccines Against Melanoma
Vaccines Against MelanomaVaccines Against Melanoma
Vaccines Against Melanoma
 
Immunotherapeutics ( types of Immunotherapeutics & humanization antibody ther...
Immunotherapeutics ( types of Immunotherapeutics & humanization antibody ther...Immunotherapeutics ( types of Immunotherapeutics & humanization antibody ther...
Immunotherapeutics ( types of Immunotherapeutics & humanization antibody ther...
 
Cancer immunotherapy slideshare
Cancer immunotherapy slideshareCancer immunotherapy slideshare
Cancer immunotherapy slideshare
 
Tumor immunology
Tumor immunologyTumor immunology
Tumor immunology
 
Cancer vaccine
Cancer vaccineCancer vaccine
Cancer vaccine
 
TUMOR IMMUNOLOGY.ppt
TUMOR IMMUNOLOGY.pptTUMOR IMMUNOLOGY.ppt
TUMOR IMMUNOLOGY.ppt
 
Immunotherapy for cancer
Immunotherapy for cancerImmunotherapy for cancer
Immunotherapy for cancer
 
tumor immunity
tumor immunitytumor immunity
tumor immunity
 
Developments in precision/personalized therapies: Robert Petit (Advaxis)
Developments in precision/personalized therapies: Robert Petit (Advaxis)Developments in precision/personalized therapies: Robert Petit (Advaxis)
Developments in precision/personalized therapies: Robert Petit (Advaxis)
 
Interaction of Radiation with Immunotherapy
Interaction of Radiation with ImmunotherapyInteraction of Radiation with Immunotherapy
Interaction of Radiation with Immunotherapy
 
immunostimulants
immunostimulantsimmunostimulants
immunostimulants
 
cellular and molecular pharmacology - presentation
cellular and molecular pharmacology - presentationcellular and molecular pharmacology - presentation
cellular and molecular pharmacology - presentation
 
14.tumor immunology and immunotherapy
14.tumor  immunology and immunotherapy14.tumor  immunology and immunotherapy
14.tumor immunology and immunotherapy
 
Immunosurveillance,
Immunosurveillance,Immunosurveillance,
Immunosurveillance,
 
Cancer and immune system
Cancer and immune systemCancer and immune system
Cancer and immune system
 
Tumor antigens & cancer immunotherapy.pptx
Tumor antigens & cancer immunotherapy.pptxTumor antigens & cancer immunotherapy.pptx
Tumor antigens & cancer immunotherapy.pptx
 

More from DrAyush Garg

More from DrAyush Garg (20)

Overview of Carcinoma Prostate and Genetics
Overview of Carcinoma Prostate and GeneticsOverview of Carcinoma Prostate and Genetics
Overview of Carcinoma Prostate and Genetics
 
OSTEOSARCOMA
OSTEOSARCOMAOSTEOSARCOMA
OSTEOSARCOMA
 
Overview of brain tumors
Overview of brain tumorsOverview of brain tumors
Overview of brain tumors
 
Hormonal therapy in breast cancer
Hormonal therapy in breast cancerHormonal therapy in breast cancer
Hormonal therapy in breast cancer
 
Multiple myeloma
Multiple myelomaMultiple myeloma
Multiple myeloma
 
Ear carcinoma
Ear carcinomaEar carcinoma
Ear carcinoma
 
Medulloblastoma
MedulloblastomaMedulloblastoma
Medulloblastoma
 
Role of palliative care in oncology
Role of palliative care in oncologyRole of palliative care in oncology
Role of palliative care in oncology
 
Breast cancer screening, prevention and genetic counselling
Breast cancer screening, prevention and genetic counsellingBreast cancer screening, prevention and genetic counselling
Breast cancer screening, prevention and genetic counselling
 
Role of SBRT in lung cancer
Role of SBRT in lung cancerRole of SBRT in lung cancer
Role of SBRT in lung cancer
 
Role of hpv in head and neck tumors
Role of hpv in head and neck tumorsRole of hpv in head and neck tumors
Role of hpv in head and neck tumors
 
Carcinoma esophagus
Carcinoma esophagusCarcinoma esophagus
Carcinoma esophagus
 
EXTRANODAL EXTENSION
EXTRANODAL EXTENSIONEXTRANODAL EXTENSION
EXTRANODAL EXTENSION
 
Management of ca prostate
Management of ca prostateManagement of ca prostate
Management of ca prostate
 
Clinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma ProstateClinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma Prostate
 
Prognostic index in brain metastasis
Prognostic index in brain metastasisPrognostic index in brain metastasis
Prognostic index in brain metastasis
 
Supportive care and quality of life
Supportive care and quality of lifeSupportive care and quality of life
Supportive care and quality of life
 
Palliation brain, spinal and bone mets
Palliation brain, spinal and bone metsPalliation brain, spinal and bone mets
Palliation brain, spinal and bone mets
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancer
 

Recently uploaded

VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
JRRolfNeuqelet
 
Physiologic Anatomy of Heart_AntiCopy.pdf
Physiologic Anatomy of Heart_AntiCopy.pdfPhysiologic Anatomy of Heart_AntiCopy.pdf
Physiologic Anatomy of Heart_AntiCopy.pdf
MedicoseAcademics
 
Failure to thrive in neonates and infants + pediatric case.pptx
Failure to thrive in neonates and infants  + pediatric case.pptxFailure to thrive in neonates and infants  + pediatric case.pptx
Failure to thrive in neonates and infants + pediatric case.pptx
claviclebrown44
 
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose AcademicsConnective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
MedicoseAcademics
 
Difference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac MusclesDifference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac Muscles
MedicoseAcademics
 

Recently uploaded (20)

VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answers
 
Treatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas HospitalTreatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas Hospital
 
Physiologic Anatomy of Heart_AntiCopy.pdf
Physiologic Anatomy of Heart_AntiCopy.pdfPhysiologic Anatomy of Heart_AntiCopy.pdf
Physiologic Anatomy of Heart_AntiCopy.pdf
 
Face and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptxFace and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptx
 
supply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-up
supply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-upsupply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-up
supply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-up
 
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdfSEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
 
BURNS (CLASSIFICATION & MANAGEMENTS).pdf
BURNS (CLASSIFICATION & MANAGEMENTS).pdfBURNS (CLASSIFICATION & MANAGEMENTS).pdf
BURNS (CLASSIFICATION & MANAGEMENTS).pdf
 
Histopathological staining techniques used in liver diseases
Histopathological staining techniques used in liver diseasesHistopathological staining techniques used in liver diseases
Histopathological staining techniques used in liver diseases
 
ESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failureESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failure
 
How to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw materialHow to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw material
 
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
 
Storage of Blood Components- equipments, effects of improper storage, transpo...
Storage of Blood Components- equipments, effects of improper storage, transpo...Storage of Blood Components- equipments, effects of improper storage, transpo...
Storage of Blood Components- equipments, effects of improper storage, transpo...
 
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptxCreeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
 
Failure to thrive in neonates and infants + pediatric case.pptx
Failure to thrive in neonates and infants  + pediatric case.pptxFailure to thrive in neonates and infants  + pediatric case.pptx
Failure to thrive in neonates and infants + pediatric case.pptx
 
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose AcademicsConnective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
 
TEST BANK For Guyton and Hall Textbook of Medical Physiology, 14th Edition by...
TEST BANK For Guyton and Hall Textbook of Medical Physiology, 14th Edition by...TEST BANK For Guyton and Hall Textbook of Medical Physiology, 14th Edition by...
TEST BANK For Guyton and Hall Textbook of Medical Physiology, 14th Edition by...
 
Difference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac MusclesDifference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac Muscles
 
Report Back from SGO: What’s the Latest in Ovarian Cancer?
Report Back from SGO: What’s the Latest in Ovarian Cancer?Report Back from SGO: What’s the Latest in Ovarian Cancer?
Report Back from SGO: What’s the Latest in Ovarian Cancer?
 
TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...
TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...
TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...
 

Cancer vaccines final

  • 2. Historical Perspective • Oldest description of cancer was discovered in Egypt and dates back to about 3000 BC. • 1777 Nooth, surgeon to Duke of Kent, inoculated himself with cancer tissue from patient. • 1808 Alibert, physician to Louis XVIII, received an injection of breast cancer material. • In 1970s, scientists mass produced monoclonal antibodies that are specifically targeted against cancer cells. 2
  • 3. 3
  • 4. INTRODUCTION • The aim of cancer vaccines is to stimulate the immune system to be able to recognise cancer cells as abnormal and destroy them. • There are two major categories that cancer vaccines fit into: 1.Specific cancer vaccine 2.Universal cancer vaccine • Each type of cancer vaccine works on the same basic idea that the vaccine, which contains tumor cells or antigens, stimulates the patient's immune system, which produces special cells that kill cancer cells and prevent relapses of the cancer. (In Animation) 4
  • 5. Cancer vaccines are medicines that belong to a class of substances known as biological response modifiers. Biological response modifiers work by stimulating or restoring the immune system’s ability to fight infections and disease. Two broad types of cancer vaccines: •Preventive (or prophylactic) vaccines prevent cancer from developing in healthy people. •Treatment (or therapeutic) vaccines treat an existing cancer by strengthening the body’s natural defenses against the cancer. Cancer vaccines
  • 6. Antitumor response of prophylactic vaccine • Given to people who have very high risk of developing cancers that have been diagnosed with premalignant changes in tissues • Vaccine based antigen along with immunomodulatory is introduced that activate the Langerhan's cells. • T cells are activated when the tumor antigen is presented to them along with B cells that produce tumor specific antibodies • Clonal expansion is the next process that occurs along with the memory cell formation. • In future if tumor start its growth tumor specific memory cells will be reactivated by the tumor antigen reaching lymph nodes • Secondary immune response 1.Large number of effector T cells 2.High titer of antibodies 3.Continues activation of DC at the site • Tumor will not be allowed to grow large and is easily eliminated as a result of secondary immune response.
  • 7.
  • 8. Anti tumor response of therapeutic vaccine • Administered after tumor diagnosis when tumor is interacting with immune system. • Vaccine (autologous/defined tumor antigen + immunomodulators) to activate Langerhan’s cells. • Taken up by activated Langerhan's cells and presented to T cells • B-cell activated, clonal expansion, production of tumor specific antibodies. • Migration of tumor sensitive T cells at site of tumor metastasis.(attempt to kill tumor cells expressing vaccine Ag.) • Immunosuppressive tumor microenvironment suppresses their function. • Establishment of tumor heterogeneity. Leading to lost of tumor antigen expression or resistance immune effectors mechanism evading immune evasion. • Tumor cells with antigen not recognized by T-cells and Ab. They are resistant to immune destruction.
  • 9.
  • 10. TYPES OF CANCER VACCINES: 10 Types of Cancer Vaccines Types of Cancer Vaccines Dendritic cell vaccines Antigen vaccines Tumour cell vaccine DNA vaccine Anti idiotype vaccine
  • 11. Antigen vaccine 11 • These use tumor-specific antigens - proteins displayed on a tumor cell - to stimulate the immune system. • By injecting these antigens into the cancerous area of the patient, the immune system will produce an increased amount of antibodies or cytotoxic T lymphocytes, also known as killer T cells, to attack cancer cells that carry that specific antigen. • Multiple antigens can be used in this type of vaccine to vary the immune system response.
  • 12. Anti-idiotype Vaccines: • Some antibodies, called idiotype antibodies, act as antigens, triggering an immune response. • Primary target is LYMPHOMA. 12
  • 13. Dendritic Cell Vaccines: • Dendritic cells break the antigens on the cancer cell surfaces into smaller pieces. • The dendritic cells then act as most-wanted posters for the immune system, displaying those antigen pieces to the killer T cells. • In order to make dendritic cell vaccines some of the patient's dendritic cells are extracted and immune cell stimulants are used to reproduce large amounts of dendritic cells in the lab. • These dendritic cells are then exposed to antigens from the patient's cancer cells. • This combination of dendritic cells and antigens is then injected into the patient and the dendritic cells work to program the T cells. 13
  • 14. Tumor Cell Vaccines (Autologous /Allogeneic Tumor Cells): • Autologous and allogeneic tumor cells were one of the first types of tumor vaccines to be used. • The main advantage of tumor cell vaccines is that they have all the relevant tumor antigens needed by the immune system to mount an effective antitumor response. • A second advantage is that tumor cell-based immunization allows the development of cancer vaccines without knowing the specific antigens. 14
  • 15. DNA Vaccines • Bits of DNA from the patient's cells are injected into the patient, which instructs the other cells to continuously produce certain antigens. • This DNA vaccine increases production of antigens, which forces the immune system to respond by producing more T cells. • The idea of these vaccines is that the body would be provided with a constant supply of antigens to allow the immune response to continue against the cancer. 15
  • 16. Cancer Vaccine Preparation: • Cancer vaccines are made from the person’s own cancer cells or from cells that are grown in a laboratory. • The cancer cells are treated with heat or radiation, then they become inactive and can be used for vaccine preparation. • Certain proteins may then be taken from the cancer cells and used to make a cancer vaccine. • Often a cancer vaccine will also contain substances that are already known to boost the immune system, such as BCG. 16
  • 18. • Mode of Delivery: Cancer vaccines are usually a liquid which is given by an intradermal injection. • The Possible Side Effects: The possible side effects of cancer vaccines include a skin reaction at the injection site, a skin rash or mild flu-like symptoms. 18
  • 19. Cancer Vaccines Which Are Currently under Clinical Trials: • Onyvax: (a monoclonal antibody 105AD7 anti-idiotype vaccine) • It is used for the treatment of advanced colorectal adenocarcinoma. • The vaccine is administered endemic together with the BCG vaccine or intramuscularly together with the alum adjuvant. 19 • OncoVAX • Autologous vaccine for Stage II colon cancer. • Received fast-track status from FDA in 2006. • STUDY: 254 patients received either OncoVAX or placebo. • Improves 5-year survival and recurrence-free interval. • 57.1% relative risk reduction.
  • 20. Cancer VAX • It is being used together with the surgical treatment in the treatment of melanoma III stage. • In order to increase the cellular immune response, this vaccine is given together with the BCG Vaccine. 20 NY-ESO-1 Peptide Vaccine • It is used endermic in the treatment of Soft tissue Sarcoma Stage II- IV expressing NY-ESO-1,LAGE antigen NY-ESO-1 or LAGE antigen . • Granulocyte-macrophage colony stimulating factor (GM- CSF) is to be injected, subcutaneous, in additional to this vaccine.
  • 21. A Monoclonal Antibody 11D10Anti- idiotype Vaccine and Monoclonal Antibody 3h1 Anti-idiotype Vaccine • They are being used in the treatment of the patients with stage II or IIIA non-small cell lung cancer (T1-3, N1-2, M0) • It is administered starting from the 14-45 days after operation. 21
  • 22. GP100 AND MART-1 • A vaccine therapy using Tyrosinase, GP100 and MART-1 peptides together with the alum adjuvant is being used for the treatment of the patients with IIB IIC, III, or IV cutaneous melanoma OR stage III or IV ocular or mucosal melanoma. • Interleukin-12 and the granulocyte-macrophage colony- stimulating factor (GM-CSF) are also used beside the vaccine. 22
  • 23. ALVAC-CEA/B7.1 • A deactivated strain of a virus, is being tested for the treatment of metastatic colorectal cancer. • Virus antigens are identical to the antigens exhibited by colorectal tumors. • The vaccine is administered immediately upon diagnosis along with chemotherapy. 23
  • 24. VG-1000 Vaccine • This vaccine is most beneficial in treating carcinomas and melanomas. • Patients subjected to chemotherapy or radiation respond more slowly to VG-1000 as they have a depressed immune system, however, patients who have had neither radiation nor chemotherapy respond favourably indicating it as first-line treatment for persons with recently diagnosed cancers, as well as to help prevent recurrence. 24
  • 25. HSPPC-96, or Oncophage® • The vaccine is a heat-shock protein, a class of compounds that has shown activity as autologous therapy • The therapeutic agent is derived from and tailored to the tumors of individual patients. • The HSPPC-96 vaccine contains antigens extracted from melanoma. • Some of these antigens, like MART-1 and GP100, are unique to melanoma; others are found in many types of cancer. 25
  • 26. Sipuleucel-T • Dendritic cell vaccine approved for treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer. • Target-prostatic acid phosphatase (PAP), which is found in 95% of prostate cancers.
  • 27. • RESULTS • In the sipuleucel-T group, there was a relative reduction of 22% in the risk of death as compared with the placebo group. • This reduction represented a 4.1-month improvement in median survival. • The 36-month survival probability was 31.7% in the sipuleucel-T group versus 23.0% in the placebo group. • CONCLUSIONS • The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer. • No effect on the time to disease progression was observed. 27
  • 29. DOSAGE AND ADMINISTRATION • For intravenous use only. • Administer 3 doses at approximately 2-week intervals. • Premedicate patients with oral acetaminophen and an antihistamine. • Infuse Sipuleucel-T intravenously over 60 minutes. • The most common adverse reactions (incidence ≥ 15%) are chills, fatigue, fever, back pain, nausea, joint ache, and headache. 29  Note: The three-course treatment will cost $93,000.
  • 31. 31
  • 32. HPV Vaccine • Gardasil: The FDA approved Gardasil for people ages 9 to 26 years to prevent: • Cervical, vaginal, and vulvar cancers in girls and women • Anal cancer in women and men • Genital warts in men and boys • The vaccine protects against the human papillomavirus (HPV). • Cervarix: This vaccine also protects against HPV infection. The FDA approved it for the prevention of cervical cancer in girls and women ages 9 to 25 years. • The first HPV vaccine became available in 2006. 32
  • 33. • According to Centers for Disease Control and Prevention (CDC) Guidelines and Advisory Committee on Immunization Practices (ACIP) November 4,2016. • HPV vaccination is not currently recommended for women over age 26 years. • Clinical trials showed that, overall, HPV vaccination offered women limited or no protection against HPV-related diseases. • For women over age 26 years, the best way to prevent cervical cancer is to get routine cervical cancer screening, as recommended. • Available vaccines protect against either two, four, or nine types of HPV so they are either Bivalent, Quadrivalent or Ninevalent respectively. 33
  • 34. Gardasil 9 • Gardasil 4 got approval by FDA in 2006 Gardasil 9 in Dec,2014. • GARDASIL 9 is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases: • Cervical, vulvar, vaginal, and anal cancer caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58 • Genital warts (condyloma acuminata) caused by HPV types 6 and 11 • GARDASIL 9 is indicated in boys and men 9 through 26 years of age for the prevention of the following diseases: • Anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58 • Genital warts (condyloma acuminata) caused by HPV types 6 and 11 34
  • 35. 35 Age Regimen Schedule 9 through 14 years 2 dose 0,6 to 12 months 3 dose 0,2,6 months 15 through 26 years 3 dose 0,2,6 months • Each dose of GARDASIL 9 is 0.5-mL. • GARDASIL 9 should be administered intramuscularly in the deltoid region of the upper arm or in the higher anterolateral area of the thigh. • All three vaccines are given through a series of three injections into muscle tissue over a 6-month period. • In October 2016, the FDA approved a 2-dose schedule for boys and girls initiating vaccination with Gardasil 9 at ages 9 to 14 years (the second dose is to be administered 6–12 months after the first)
  • 36. Cervarix • CERVARIX is a vaccine indicated for the prevention of the following diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18: • Cervical cancer, • Cervical intraepithelial neoplasia (CIN) Grade 2 or worse and adenocarcinoma in situ, and • Cervical intraepithelial neoplasia (CIN) Grade 1. • CERVARIX is approved for use in females 9 through 25 years of age. • Three doses (0.5-mL each) by intramuscular injection according to the following schedule: 0, 1, and 6 months. • The preferred site of administration is the deltoid region of the upper arm. 36
  • 37. Role of Adjuvants in cancer vaccines? • Substances known as adjuvants are often added to vaccines to boost their ability to induce potent anticancer immune responses. • Some microbes, such as the bacterium Bacillus Calmette- Guérin (BCG). • BCG is used to treat early stage bladder cancer. It is a liquid put into the bladder through a catheter. • BCG attracts the body’s immune system cells to the bladder, where they can attack the bladder cancer cells. • Treatment with BCG can cause symptoms that are like: • Flu like symptoms such as fever, chills, and fatigue. • It can also cause a burning feeling in the bladder. 37
  • 38. Side Effects of Cancer Vaccine • The most commonly reported side effect of cancer vaccines is • Inflammation at the site of injection, including redness, pain, swelling, warming of the skin, itchiness, and occasionally a rash. • People sometimes experience flu-like symptoms after receiving a cancer vaccine, including fever, chills, weakness, dizziness, nausea or vomiting, muscle ache, fatigue, headache, and occasional breathing difficulties. • These side effects, which usually last for only a short time, indicate that the body is responding to the vaccine and making an immune response, as it does when exposed to a virus. 38
  • 39. • Thalidomide: • treatment for multiple myeloma • Lenalidomide: • Newer drug , treatment for multiple myeloma • Bacille Calmette-Guérin: • treatment of superficial forms of bladder cancer • Colorectal cancer • Lung cancer • Melanoma • Medicinal mushrooms: • Agaricus subrufescens -anticancer properties Other drugs that boost the immune system
  • 40. 40
  • 41. 41
  • 42. CONCLUSION: May be more effective in cancers that are not advanced. More research still needs to be done including larger studies. Researchers are actively trying to overcome hurdles in the making of these vaccines. Could make a big impact on our approach to cancer. Most importantly these vaccines could mean better quality of life and longer survival for patients!! 42

Editor's Notes

  1. CYTOTOXIC T LYMPHOCYTES
  2. Medical need great 30,000 deaths a year from this cancer. Most common noncutaneous cancer in men.
  3. Antigen presenting cells